Mobia Medical’s (MOBI) “Buy” Rating Reiterated at BTIG Research

Mobia Medical (NASDAQ:MOBI)‘s stock had its “buy” rating restated by stock analysts at BTIG Research in a research note issued on Tuesday, Benzinga reports. They currently have a $19.00 target price on the stock. BTIG Research’s price target suggests a potential upside of 113.24% from the stock’s previous close.

MOBI has been the topic of several other reports. JPMorgan Chase & Co. upped their price target on shares of Mobia Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Weiss Ratings initiated coverage on shares of Mobia Medical in a research note on Wednesday, August 12th. They issued a “sell (e-)” rating for the company. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $20.75.

Mobia Medical Price Performance

NASDAQ MOBI traded up $0.10 on Tuesday, reaching $8.91. The stock had a trading volume of 14,627 shares, compared to its average volume of 173,033. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.80 and a current ratio of 13.28. The stock has a market capitalization of $296.61 million and a P/E ratio of -0.44. The stock’s fifty day moving average is $10.21. Mobia Medical has a 1-year low of $8.03 and a 1-year high of $15.29.

Mobia Medical (NASDAQ:MOBI) last posted its earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The firm had revenue of $13.51 million during the quarter. The company’s revenue for the quarter was up 102.4% compared to the same quarter last year. Research analysts predict that Mobia Medical will post -2.63 EPS for the current fiscal year.

Insider Transactions at Mobia Medical

In other news, Director Casey Tansey bought 16,441 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were purchased at an average cost of $12.07 per share, with a total value of $198,442.87. Following the acquisition, the director directly owned 318,332 shares in the company, valued at $3,842,267.24. This represents a 5.45% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought 87,000 shares of company stock worth $1,016,367 in the last 90 days.

Institutional Trading of Mobia Medical

A number of institutional investors and hedge funds have recently made changes to their positions in MOBI. Readystate Asset Management LP acquired a new stake in shares of Mobia Medical during the 2nd quarter worth approximately $134,000. Citadel Advisors LLC acquired a new position in Mobia Medical during the second quarter valued at approximately $670,000. Finally, State Street Corp acquired a new position in Mobia Medical during the second quarter valued at approximately $735,000.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.